ICON plc Revenue and Competitors

Claim your profile

Boston, MA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • ICON plc's estimated annual revenue is currently $4.4B per year.(i)
  • ICON plc's estimated revenue per employee is $117,025
  • ICON plc's current valuation is $21.2B. (January 2022}

Employee Data

  • ICON plc has 37257 Employees.(i)
  • ICON plc grew their employee count by 175% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$30717M8126213%N/AN/A

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times.

keywords:N/A

N/A

Total Funding

37257

Number of Employees

$4.4B

Revenue (est)

175%

Employee Growth %

$21.2B

Valuation

N/A

Accelerator

ICON plc News

2022-04-20 - IQVIA Holdings Inc. stock falls Tuesday, underperforms market

CRL, -8.55% fell 8.55% to $231.67, and Icon PLC ICLR, -6.63% fell 6.63% to $210.67. Trading volume (2.1 M) eclipsed its 50-day average volume of...

2022-04-20 - IQVIA Holdings Inc. stock falls Tuesday, underperforms market

CRL, -8.55% fell 8.55% to $231.67, and Icon PLC ICLR, -6.63% fell 6.63% to $210.67. Trading volume (2.1 M) eclipsed its 50-day average volume of...

2022-04-19 - Medical Device Contract Research Organization Market Key ...

... Research Organization Market Key Insights Based on Product Type, End-use and Regional Demand 2021-2030 | Icon Plc, IQVIA, Covance...

2022-04-19 - Medical Device Contract Research Organization Market Key ...

... Research Organization Market Key Insights Based on Product Type, End-use and Regional Demand 2021-2030 | Icon Plc, IQVIA, Covance...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14515.7M493735%N/A
#2
$11920M53612N/AN/A
#3
$18366M5779117%N/A
#4
$11055.6M607451%N/A
#5
$2147.5M74930N/AN/A